Skip to main content
Top
Published in: Diabetes Therapy 6/2018

Open Access 01-12-2018 | Original Research

Insulin Injection Technique in China Compared with the Rest of the World

Authors: Zhenqiang Song, Xiaohui Guo, Linong Ji, Xiao Huang, Laurence J. Hirsch, Kenneth W. Strauss

Published in: Diabetes Therapy | Issue 6/2018

Login to get access

Abstract

Introduction

Approximately 9 million people in China use insulin but little is known of their injection techniques (IT). Our aim was to understand IT in China via direct examination and a detailed survey.

Methods

Injection Technique Questionnaire (ITQ) results of 3853 patients from 20 representative centers in China were compared with the Rest of World (ROW).

Results

Insulin pens are used by 92% of Chinese insulin injectors, with > 3/4 using 4- or 5-mm pen needles. This is consistent with Chinese BMI values (and thus subcutaneous fat thickness) being lower than in ROW, raising the risk of IM (intramuscular) injections with longer needles. Total daily insulin dose is ~ 33 IU in China vs. 45 IU elsewhere. Lipohypertrophy (LH) rates are lower than in ROW, but still found in at least 25% of Chinese patients. Patients apparently do not realize they have LH or are unaware of the hazards of injecting into LH since many of them do so, and those who do use a mean of 11 IU more of insulin than non-LH patients. This incremental insulin use possibly costs the Chinese health care service around 2 billion RMB annually. Needle reuse is also frequent in China (78% vs. 48% ROW), and the high cost of pen needles is the main reason patients cite for reusing (25% use a single needle > 10×).

Conclusion

This study reveals many areas in which Chinese professionals and patients can optimize injection practices and thereby improve outcomes and reduce costs. The official guidelines of the Chinese Diabetes Society, based on the FITTER recommendations, offer a roadmap for reaching this goal.

Funding

BD Diabetes Care.

Plain Language Summary

Plain language summary available for this article.
Literature
6.
go back to reference Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103(2):137–49.CrossRefPubMed Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103(2):137–49.CrossRefPubMed
7.
go back to reference Wang W, et al. Skin and subcutaneous tissue thickness at insulin injection sites in Chinese diabetes patients: clinical implications. Diabetes Metab. 2016;42:374–7.CrossRefPubMed Wang W, et al. Skin and subcutaneous tissue thickness at insulin injection sites in Chinese diabetes patients: clinical implications. Diabetes Metab. 2016;42:374–7.CrossRefPubMed
8.
go back to reference Jiajia J, Qingqing L. Insulin pen injection technique survey in patients with type 2 diabetes in mainland China in 2010. CMRO. 2014;30:1087–93. Jiajia J, Qingqing L. Insulin pen injection technique survey in patients with type 2 diabetes in mainland China in 2010. CMRO. 2014;30:1087–93.
9.
go back to reference Ji L, Guo X, Huang J, et al. Chinese guideline for diabetic injection technology. Chin J Diabetes Mellitus. 2017;9(2):79–105. Ji L, Guo X, Huang J, et al. Chinese guideline for diabetic injection technology. Chin J Diabetes Mellitus. 2017;9(2):79–105.
20.
go back to reference Gentile S, Guarino G, Giancaterini A, Guida P, Strollo F, AMD-OSDI Italian Injection Technique Study Group. A suitable palpation technique allows to identify skin lipohypertrophic lesions in insulin-treated people with diabetes. Springerplus. 2016;5:563. https://doi.org/10.1186/s40064-016-1978-y (eCollection 2016). Gentile S, Guarino G, Giancaterini A, Guida P, Strollo F, AMD-OSDI Italian Injection Technique Study Group. A suitable palpation technique allows to identify skin lipohypertrophic lesions in insulin-treated people with diabetes. Springerplus. 2016;5:563. https://​doi.​org/​10.​1186/​s40064-016-1978-y (eCollection 2016).
22.
go back to reference Vaag A, et al. Variation in absorption of NPH insulin due to Intramuscular injection. Diabetes Care. 1990;13(1):74–6.CrossRefPubMed Vaag A, et al. Variation in absorption of NPH insulin due to Intramuscular injection. Diabetes Care. 1990;13(1):74–6.CrossRefPubMed
24.
go back to reference Gibney MA, Arce CH, Byron KJ, Hirsch LJ. Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations. Curr Med Res Opin. 2010;26(6):1519–30.CrossRefPubMed Gibney MA, Arce CH, Byron KJ, Hirsch LJ. Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations. Curr Med Res Opin. 2010;26(6):1519–30.CrossRefPubMed
25.
go back to reference Hirsch L, Klaff L, Bailey T, Gibney M, Albanese J, Qu S, Kassler-Taub K. Comparative glycemic control, safety and patient ratings for a new 4 mm\32G insulin pen needle in adults with diabetes. Curr Med Res Opin. 2010;26:1531–41.CrossRefPubMed Hirsch L, Klaff L, Bailey T, Gibney M, Albanese J, Qu S, Kassler-Taub K. Comparative glycemic control, safety and patient ratings for a new 4 mm\32G insulin pen needle in adults with diabetes. Curr Med Res Opin. 2010;26:1531–41.CrossRefPubMed
26.
go back to reference Wang W, Guo X, Shen G, et al. Skin and subcutaneous tissue thickness at insulin injection sites in Chinese diabetes patients: clinical implications. Diabetes Metab. 2016;42(5):374–7.CrossRefPubMed Wang W, Guo X, Shen G, et al. Skin and subcutaneous tissue thickness at insulin injection sites in Chinese diabetes patients: clinical implications. Diabetes Metab. 2016;42(5):374–7.CrossRefPubMed
27.
go back to reference Jain SM, Pandey K, Lahoti A, Rao PK. Evaluation of skin and subcutaneous tissue thickness at insulin injection sites in Indian, insulin naïve, type-2 diabetic adult population. Indian J Endocrinol Metab. 2013;17(5):864–70.CrossRefPubMedPubMedCentral Jain SM, Pandey K, Lahoti A, Rao PK. Evaluation of skin and subcutaneous tissue thickness at insulin injection sites in Indian, insulin naïve, type-2 diabetic adult population. Indian J Endocrinol Metab. 2013;17(5):864–70.CrossRefPubMedPubMedCentral
28.
go back to reference Catambing I, Villa M. Ultrasonographic measurement of skin and subcutaneous thickness at insulin injection sites among adult filipinos with diabetes. J ASEAN Feder Endocr Soc. 2014;29(1):24–32. Catambing I, Villa M. Ultrasonographic measurement of skin and subcutaneous thickness at insulin injection sites among adult filipinos with diabetes. J ASEAN Feder Endocr Soc. 2014;29(1):24–32.
29.
go back to reference Sim KH, Hwang MS, Kim SY, Lee HM, Chang JY, Lee MK. The appropriateness of the length of insulin needles based on determination of skin and subcutaneous fat thickness in the abdomen and upper arm in patients with type 2 diabetes. Diabetes Metab J. 2014;38(2):120–33.CrossRefPubMedPubMedCentral Sim KH, Hwang MS, Kim SY, Lee HM, Chang JY, Lee MK. The appropriateness of the length of insulin needles based on determination of skin and subcutaneous fat thickness in the abdomen and upper arm in patients with type 2 diabetes. Diabetes Metab J. 2014;38(2):120–33.CrossRefPubMedPubMedCentral
31.
go back to reference Lo Presti D, Ingegnosi C, Strauss K. Skin and subcutaneous thickness at injecting sites in children with diabetes: ultrasound findings and recommendations for giving injection. Pediatr Diabetes. 2012;13(7):525–33.CrossRefPubMed Lo Presti D, Ingegnosi C, Strauss K. Skin and subcutaneous thickness at injecting sites in children with diabetes: ultrasound findings and recommendations for giving injection. Pediatr Diabetes. 2012;13(7):525–33.CrossRefPubMed
32.
go back to reference Hirsch L, Byron K, Gibney M. Intramuscular risk at insulin injection sites-measurement of the distance from skin to muscle and rationale for shorter-length needles for subcutaneous insulin therapy. Diabetes Technol Ther. 2014;16(12):867–73.CrossRefPubMed Hirsch L, Byron K, Gibney M. Intramuscular risk at insulin injection sites-measurement of the distance from skin to muscle and rationale for shorter-length needles for subcutaneous insulin therapy. Diabetes Technol Ther. 2014;16(12):867–73.CrossRefPubMed
33.
go back to reference Kreugel G, Keers JC, Jongbloed A, Verweij-Gjaltema AH, Wolffenbuttel BHR. The influence of needle length on glycemic control and patient preference in obese diabetic patients. Diabetes. 2009;58:A117. Kreugel G, Keers JC, Jongbloed A, Verweij-Gjaltema AH, Wolffenbuttel BHR. The influence of needle length on glycemic control and patient preference in obese diabetic patients. Diabetes. 2009;58:A117.
34.
go back to reference Hirsch L, Klaff L, Bailey T, et al. Comparative glycemic control, safety and patient ratings for a new 4 mm × 32G insulin pen needle in adults with diabetes. Curr Med Res Opin. 2010;26(6):1531–41.CrossRefPubMed Hirsch L, Klaff L, Bailey T, et al. Comparative glycemic control, safety and patient ratings for a new 4 mm × 32G insulin pen needle in adults with diabetes. Curr Med Res Opin. 2010;26(6):1531–41.CrossRefPubMed
35.
go back to reference Schwartz S, Hassman D, Shelmet J, et al. A multicenter, open-label, randomized, two-period crossover trial comparing glycemic control, satisfaction, and preference achieved with a 31 gauge × 6 mm needle versus a 29 gauge × 12.7 mm needle in obese patients with diabetes mellitus. Clin Ther. 2004;26(10):1663–78.CrossRefPubMed Schwartz S, Hassman D, Shelmet J, et al. A multicenter, open-label, randomized, two-period crossover trial comparing glycemic control, satisfaction, and preference achieved with a 31 gauge × 6 mm needle versus a 29 gauge × 12.7 mm needle in obese patients with diabetes mellitus. Clin Ther. 2004;26(10):1663–78.CrossRefPubMed
36.
go back to reference Ross SA, Jamal R, Leiter LA, et al. Evaluation of 8 mm insulin pen needles in people with type 1 and type 2 diabetes. Pract Diabetes Int. 1999;16(5):145–8.CrossRef Ross SA, Jamal R, Leiter LA, et al. Evaluation of 8 mm insulin pen needles in people with type 1 and type 2 diabetes. Pract Diabetes Int. 1999;16(5):145–8.CrossRef
37.
go back to reference Strauss K, Hannet I, McGonigle J, et al. Ultra-short (5 mm) insulin needles: trial results and clinical recommendations. Pract Diabetes Int. 1999;16(7):218–21.CrossRef Strauss K, Hannet I, McGonigle J, et al. Ultra-short (5 mm) insulin needles: trial results and clinical recommendations. Pract Diabetes Int. 1999;16(7):218–21.CrossRef
38.
go back to reference Kreugel G, Keers JC, Kerstens MN, Wolffenbuttel BH. Randomized trial on the influence of the length of two insulin pen needles on glycemic control and patient preference in obese patients with diabetes. Diabetes Technol Ther. 2011;13(7):737–41.CrossRefPubMedPubMedCentral Kreugel G, Keers JC, Kerstens MN, Wolffenbuttel BH. Randomized trial on the influence of the length of two insulin pen needles on glycemic control and patient preference in obese patients with diabetes. Diabetes Technol Ther. 2011;13(7):737–41.CrossRefPubMedPubMedCentral
39.
go back to reference Iwanaga M, Kamoi K. Patient perceptions of injection pain and anxiety: a comparison of NovoFine 32-gauge tip 6 mm and Micro Fine Plus 31-gauge 5 mm needles. Diabetes Technol Ther. 2009;11(2):81–6.CrossRefPubMed Iwanaga M, Kamoi K. Patient perceptions of injection pain and anxiety: a comparison of NovoFine 32-gauge tip 6 mm and Micro Fine Plus 31-gauge 5 mm needles. Diabetes Technol Ther. 2009;11(2):81–6.CrossRefPubMed
40.
go back to reference McKay M, Compion G, Lytzen L. A comparison of insulin injection needles on patients’ perceptions of pain, handling, and acceptability: a randomized, open-label, crossover study in subjects with diabetes. Diabetes Technol Ther. 2009;11(3):195–201.CrossRefPubMed McKay M, Compion G, Lytzen L. A comparison of insulin injection needles on patients’ perceptions of pain, handling, and acceptability: a randomized, open-label, crossover study in subjects with diabetes. Diabetes Technol Ther. 2009;11(3):195–201.CrossRefPubMed
41.
go back to reference Nagai Y, Ohshige T, Arai K, Kobayashi H, Sada Y, Ohmori S. Comparison between shorter straight and thinner microtapered insulin injection needles. Diabetes Technol Ther. 2013;15(7):550–5.CrossRefPubMed Nagai Y, Ohshige T, Arai K, Kobayashi H, Sada Y, Ohmori S. Comparison between shorter straight and thinner microtapered insulin injection needles. Diabetes Technol Ther. 2013;15(7):550–5.CrossRefPubMed
42.
go back to reference Hirose T, Ogihara T, Tozaka S, Kanderian S, Watada H. Identification and comparison of insulin pharmacokinetics injected with a new 4-mm needle vs 6- and 8-mm needles accounting for endogenous insulin and C-peptide secretion kinetics in non-diabetic adult males. J Diabetes Investig. 2013;4(3):287–96.CrossRefPubMedPubMedCentral Hirose T, Ogihara T, Tozaka S, Kanderian S, Watada H. Identification and comparison of insulin pharmacokinetics injected with a new 4-mm needle vs 6- and 8-mm needles accounting for endogenous insulin and C-peptide secretion kinetics in non-diabetic adult males. J Diabetes Investig. 2013;4(3):287–96.CrossRefPubMedPubMedCentral
43.
go back to reference De Coninck C, Frid A, Gaspar R, et al. Results and analysis of the 2008–2009 insulin injection technique questionnaire survey. J Diabetes. 2010;2(3):168–79.CrossRefPubMed De Coninck C, Frid A, Gaspar R, et al. Results and analysis of the 2008–2009 insulin injection technique questionnaire survey. J Diabetes. 2010;2(3):168–79.CrossRefPubMed
44.
go back to reference Vardar B, Kizilci S. Incidence of lipohypertrophy in diabetic patients and a study of influencing factors. Diabetes Res Clin Pract. 2007;77:231–6.CrossRefPubMed Vardar B, Kizilci S. Incidence of lipohypertrophy in diabetic patients and a study of influencing factors. Diabetes Res Clin Pract. 2007;77:231–6.CrossRefPubMed
45.
go back to reference Saez-de Ibarra L, Gallego F. Factors related to lipohypertrophy in insulin-treated diabetic patients; role of educational intervention. Pract Diab Int. 1998;15:9–11.CrossRef Saez-de Ibarra L, Gallego F. Factors related to lipohypertrophy in insulin-treated diabetic patients; role of educational intervention. Pract Diab Int. 1998;15:9–11.CrossRef
46.
go back to reference Blanco M, Hernández MT, Strauss KW, Amaya M. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes Metab. 2013;39(5):445–53.CrossRefPubMed Blanco M, Hernández MT, Strauss KW, Amaya M. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes Metab. 2013;39(5):445–53.CrossRefPubMed
47.
go back to reference Hirsch L, Ji L, Sun Z, Li Q, et al. Lipohypertrophy—prevalence, risk factors and clinical characteristics of insulin-requiring patients in China. DTT. 2015;17(Suppl 1):A57–8. Hirsch L, Ji L, Sun Z, Li Q, et al. Lipohypertrophy—prevalence, risk factors and clinical characteristics of insulin-requiring patients in China. DTT. 2015;17(Suppl 1):A57–8.
48.
go back to reference Misnikova I, Dreval A, Gubkina V, Rusanova E. The risk of repeated use of insulin pen needles in patients with diabetes mellitus. J Diabetol. 2011;1:1–5. Misnikova I, Dreval A, Gubkina V, Rusanova E. The risk of repeated use of insulin pen needles in patients with diabetes mellitus. J Diabetol. 2011;1:1–5.
49.
go back to reference Smith M, Clapham L, Strauss K. UK lipohypertrophy intervention study. Diabetes Res Clin Pract. 2017;126:248–53.CrossRefPubMed Smith M, Clapham L, Strauss K. UK lipohypertrophy intervention study. Diabetes Res Clin Pract. 2017;126:248–53.CrossRefPubMed
Metadata
Title
Insulin Injection Technique in China Compared with the Rest of the World
Authors
Zhenqiang Song
Xiaohui Guo
Linong Ji
Xiao Huang
Laurence J. Hirsch
Kenneth W. Strauss
Publication date
01-12-2018
Publisher
Springer Healthcare
Published in
Diabetes Therapy / Issue 6/2018
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI
https://doi.org/10.1007/s13300-018-0525-y

Other articles of this Issue 6/2018

Diabetes Therapy 6/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.